# Treatment of Ovarian Clear Cell Carcinoma: A Case of Successful Management With Targeted Therapies

## TL;DR

A patient with advanced ovarian clear cell carcinoma responded well to targeted therapies after standard treatments failed.

## Contribution

Demonstrates successful use of alpelisib and immunotherapy in treating resistant ovarian clear cell carcinoma.

## Key findings

- Alpelisib provided a durable response based on genomic testing.
- Nivolumab and ipilimumab combination showed partial response after alpelisib progression.
- Targeted therapies offer promising options for advanced ovarian clear cell carcinoma.

## Abstract

Background: Advanced stages of ovarian clear cell carcinoma have poorer prognoses than many other ovarian cancers. When standard treatments are ineffective, alternative options are needed.

Case: A 56-year-old woman was diagnosed with ovarian clear cell carcinoma and treated with surgical management as well as carboplatin and paclitaxel. At recurrence, her disease progressed despite multiple chemotherapy regimens. A durable response was achieved first with alpelisib, chosen based on genomic testing. When progression occurred on this agent, a partial disease response was achieved with the combination of nivolumab and ipilimumab.

Conclusion: The use of targeted therapies as well as the combination of nivolumab and ipilimumab is a promising option in advanced and recurrent cases of ovarian clear cell carcinoma.